Popular Trials
Neurotoxin
Botox for Migraine
Botox acts on nerve endings, yet there are no nerve endings inside the muscle, where they are typically injected. All nerves terminate on the fascia, where ASIS device can precisely deliver Botox by creating that subdermal bloodless space, between the skin and muscle. Thus enhancing and prolonging Botox's efficacy, at the same time prevent it's unnecessary adverse reactions and distant spread, especially since Botox has no reason to travel to the rest of the body any way.
Group 1 for Menstrual Migraine
This study will examine the combined effects of a continuous oral contraceptive (OC) regimen with supplemental estradiol therapy on headache severity and occurrence in subjects with documented Menstrually Associated Migraines (MAMs). The subjects enrolling in the study will have cyclic menses either due to spontaneous ovulation or use of cyclic hormonal contraception (pill, patch, or ring). Enrolled subjects will start a continuous OC regimen following two baseline menstrual cycles. If breakthrough bleeding/spotting (BTB/BTS) occurs, the subject will institute a 4-day hormone-free interval (HFI). In an attempt to prevent/lessen the severity of headache during the HFI, subjects will be randomized to oral estradiol or placebo during this period. If no BTB/BTS occurs after 80 days of continuous pills, the subject will institute a 4-day HFI during which they will be randomized into estradiol or placebo groups. The purpose of this research study is to examine the effects of continuous oral contraceptive pills and oral estradiol on headaches that occur around the time of your period. Many woman take continuous oral contraceptive pills (OC) and when OCs are stopped they may get headaches. This study will examine if taking estradiol around the time of the period will affect the headache, and how it will be affected. This study is a prospective trial. A subject's participation will last approximately 32 weeks.
Behavioural Intervention
Mental Efficacy Workload Test (MEWT) +1 More for Migraine
Migraine headache occurs frequently in women more than men and is associated with symptoms not only of significant pain but also of symptoms typically including of photophobia, phonophobia, nausea and vomiting. Many migraine patients report difficulty in cognition from lack of concentration, difficulty in word finding or inability to remember. Many of these cognitive symptoms seem to be independent of the pain intensity and may occur completely separately from the headache pain but can be disabling. It is likely that the frequency and importance of cognitive symptoms associated with migraine are underreported. The Mental Efficacy Workload Test (MEWT) is a computerized battery that is designed to be an efficient and accurate measure of cognition during migraine headache. Treximet is a new migraine treatment recently FDA approved for the treatment for the relief of acute migraine that may be effective for the cognitive symptoms for migraine patients who have a history of cognitive dysfunction during a migraine headache. The primary efficacy parameter is to evaluate the effectiveness of treatment with Treximet versus placebo in patients with acute migraine headache measuring neuropsychological function using the MEWT during the migraine and comparing that score with a prior MEWT score when the patient had no migraine symptoms. A double blind, placebo-controlled, crossover study was chosen so that each patient may be her or his own control. It is the intent of this study to determine the type and intensity of cognitive dysfunction associated with migraine headache and to what extent that Treximet may relieve the cognitive dysfunction in a safe and effective manner.
Corticosteroid
Dexamethasone +2 More for Migraine
This trial tests a new treatment for people with chronic migraines and facial pain that haven't responded to other treatments. The treatment involves injecting a mix of a steroid, a pain reliever, and a vitamin into specific nerves in the head and neck. This combination aims to reduce overactive pain signals and provide long-term relief.
Popular Filters
Trials for MA Patients
Corticosteroid
Lidocaine + Steroid Injections for Migraines
This trial aims to investigate if injecting lidocaine and steroids into two blood vessels in the brain can help treat chronic migraines. The study will assess the safety and effectiveness of this treatment for chronic migraine
Procedure
Intravenous Fluids for Childhood Migraine
This trial is comparing different amounts of fluids given through an IV to children with migraines. The trial wants to find out if giving a large amount of fluids quickly can help reduce pain and prevent hospital admissions
Behavioral Intervention
Behavioral Treatment for Migraines
This trial aims to understand and improve a behavioral intervention for migraines. It will also investigate the best combinations of treatments and how people's preferences and choices can affect the trial outcomes.
Corticosteroid
CBT + Amitriptyline for Childhood Migraine
This trial will compare Cognitive Behavioral Therapy (CBT) via telehealth with a pill-based preventive therapy (amitriptyline) for treating childhood migraine. Results will help provide evidence-based, accessible care.
Trials for Headache Patients
Behavioral Intervention
Behavioral Treatment for Migraines
This trial aims to understand and improve a behavioral intervention for migraines. It will also investigate the best combinations of treatments and how people's preferences and choices can affect the trial outcomes.
Corticosteroid
CBT + Amitriptyline for Childhood Migraine
This trial will compare Cognitive Behavioral Therapy (CBT) via telehealth with a pill-based preventive therapy (amitriptyline) for treating childhood migraine. Results will help provide evidence-based, accessible care.
Behavioral Intervention
Mind-Body Balance for Pediatric Migraine
This trial is testing a mind-body intervention delivered by a nurse, using different doses of three treatment components, to find the combination that works best to reduce the number of headache days.
Nerve Stimulator
Wearable Nerve Stimulation for Migraines and Mood Disorders
This trial tests a wrist-worn nerve stimulator to see if it can reduce pain, anxiety, depression & sleep disruption in adolescents with chronic headaches & mood trouble. Participants wear device & complete monthly surveys for 12 weeks.
Phase 3 Trials
Nonsteroidal Anti-inflammatory Drug (NSAID)
Intra-oral Topical Ketoprofen Gel for Migraine
This trial is testing a mouth-applied pain reliever called ketoprofen to see if it helps people with sudden migraine attacks. The goal is to find out if it works well and is safe to use. Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that has been tested in various formulations for the treatment of acute migraine attacks.
Bioabsorbable Implant
BioSTAR Septal Repair Implant System for Migraine
The objective of the study is to investigate the safety and effectiveness of PFO closure with the BioSTAR Septal Repair Implant System in a population of patients that have refractory migraine (with aura) and who have failed medications.
Phenothiazine Antipsychotic
Prochlorperazine for Migraine
Headache is a common presenting complaint to the emergency department accounting for 1-2% of patient visits. Of these headaches, approximately 90% are migraine, tension headache, or combined presentations. The most commonly used migraine therapy in the ED is intravenous prochlorperazine, but its administration requires close nursing observation, a bed, and the insertion of an intravenous catheter. Buccal prochlorperazine represents an alternative form of delivery that enables rapid achievement of therapeutic blood levels and may lead to symptom resolution. In a randomized, controlled, prospective study,the investigators plan to assess the efficacy of buccal versus intravenous prochlorperazine for the initial emergency department treatment of migraine headaches.
Trials With No Placebo
Corticosteroid
Lidocaine + Steroid Injections for Migraines
This trial aims to investigate if injecting lidocaine and steroids into two blood vessels in the brain can help treat chronic migraines. The study will assess the safety and effectiveness of this treatment for chronic migraine
Behavioral Intervention
Behavioral Treatment for Migraines
This trial aims to understand and improve a behavioral intervention for migraines. It will also investigate the best combinations of treatments and how people's preferences and choices can affect the trial outcomes.
Corticosteroid
CBT + Amitriptyline for Childhood Migraine
This trial will compare Cognitive Behavioral Therapy (CBT) via telehealth with a pill-based preventive therapy (amitriptyline) for treating childhood migraine. Results will help provide evidence-based, accessible care.
Behavioral Intervention
Mind-Body Balance for Pediatric Migraine
This trial is testing a mind-body intervention delivered by a nurse, using different doses of three treatment components, to find the combination that works best to reduce the number of headache days.
Behavioral Intervention
Online Intervention for Migraines
This trial is testing whether an online intervention can help improve headache outcomes for adolescents with migraines, compared to an attention control intervention. The primary outcome will be the number of headache days, assessed via online daily diary pre- and post-intervention.
View More Related Trials
Frequently Asked Questions
Introduction to migraine
What are the top hospitals conducting migraine research?
When it comes to cutting-edge research and clinical trials for migraine, several top hospitals are leading the way. In Bellevue, Washington, the Northwest Clinical Research Center stands out with an impressive 12 ongoing migraine trials and a total of 37 completed trials in their history. This facility has been dedicated to studying migraines since recording its first trial in 2014. Meanwhile, Clinvest Research LLC in Springfield is making significant contributions as well with nine active migraine trials and a previous record of 17 conducted studies since initiating their inaugural trial in 2018.
Moving east to Cincinnati, Ohio, the Cincinnati Children's Hospital Medical Center is at the forefront of pediatric migraine research. With eight ongoing clinical trials focused on migraines and a total of 13 previously conducted studies since their first recorded trial in 2012, this hospital plays a critical role in advancing our understanding of this condition among children.
In Stamford, Connecticut, the New England Institute for Clinical Research is actively involved in investigating new treatments for migraines. They currently have eight active migraine trials underway and have completed a commendable sixteen studies since conducting their initial trial also back in 2012.
Not far away from Stamford lies Boston Clinical Trials where another group of medical professionals are diligently working on finding solutions for those affected by migraines. With eight ongoing clinical trials and twenty-three completed investigations under their belt dating back to their first recorded trial in 2015,
All these hospitals demonstrate dedication towards unraveling mysteries surrounding migraines through cutting-edge research approaches across different regions within the United States.With every step forward taken by these esteemed institutions brings us closer toward advancements that could potentially transform countless lives affected by this debilitating condition worldwide
Which are the best cities for migraine clinical trials?
When it comes to migraine clinical trials, several cities have emerged as hubs for cutting-edge research. Miami, Florida leads the pack with 45 active trials investigating promising treatments such as Lasmiditan, Ubrogepant, and Rimegepant / BHV3000. Cincinnati, Ohio closely follows with 38 ongoing studies exploring treatments like Rimegepant / BHV3000, Ubrogepant, and Fremanezumab. Amherst, New york also plays a significant role in migraine research with 26 active trials focusing on therapies such as Fremanezumab, Eptinezumab, and Rimegepant / BHV3000. These cities offer individuals suffering from migraines access to state-of-the-art clinical trials that pave the way for improved treatment options and quality of life.
Which are the top treatments for migraine being explored in clinical trials?
The field of migraine treatment is constantly evolving, and clinical trials are at the forefront of exploring new possibilities. Eptinezumab has emerged as a top contender with four active trials and 12 all-time migraine trials since its introduction in 2019. Fremanezumab is also proving promising, currently being tested in three ongoing trials following its listing in 2016. Additionally, Emotional Awareness and Expression Therapy (EAET) shows potential with two active trials slated for this innovative approach introduced recently in 2023. Rimegepant / BHV3000 rounds out the list with two active trials examining its effectiveness against migraines since being listed in 2021. As research progresses, these treatments offer hope for improved management and relief from the debilitating effects of migraines.
What are the most recent clinical trials for migraine?
Exciting advancements in migraine treatment have emerged from recent clinical trials. One of them involves atogepant, which has shown promise in Phase 3 trials as a potential therapy for migraines. Additionally, ReMMiD-C Therapeutic Arm A and eptinezumab 300 mg have both demonstrated positive results in Phase 3 trials, offering hope for improved migraine management. Another trial focused on the use of greater occipital nerve blocks to alleviate migraines shows encouraging potential during its Phase 2 stage. These findings provide renewed optimism for individuals seeking effective solutions to manage their migraines and improve their quality of life.
What migraine clinical trials were recently completed?
Several recent clinical trials have made significant strides in the field of migraine treatment. March 2022 saw the completion of a trial sponsored by Allergan, which investigated the effectiveness of Ubrogepant. In December 2021, Eli Lilly and Company concluded their study on Galcanezumab, while H. Lundbeck A/S wrapped up their trial on Lu AG09222 in November 2021. Other completed trials include Dihydroergotamine (June and September 2021), Fremanezumab-Vfrm (December 2020), THC ~5% and CBD ~12% (November 2020), LY3451838 (November 2020), Erenumab-Aooe (October 2020) – all with various sponsors ranging from pharmaceutical companies to academic institutions. These advancements offer hope for individuals living with migraines by expanding our understanding of potential treatments for this debilitating condition.